An Act relative to capping the price of epinephrine
Generates a plain-language summary of the bill text and history.
| Date | Branch | Action |
|---|---|---|
| 1/20/2026 | House | Bill reported favorably by committee and referred to the committee on House Ways and Means |
| 9/26/2025 | Joint | Hearing scheduled for 10/08/2025 from 10:30 AM-02:30 PM in Gardner Auditorium |
| 4/3/2025 | Senate | Senate concurred |
| 3/31/2025 | House | Discharged to the committee on Financial Services |
| 2/27/2025 | Senate | Senate concurred |
| 2/27/2025 | House | Referred to the committee on Health Care Financing |
| Committee | Recommendation | Vote |
|---|---|---|
| J24 | Discharge to Another Committee | — |
| J11 | Favorable | 1 entries |
Subsection (b) of section 26 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “members”, the following words:- ; and the following acute condition (i) anaphylaxis.
Subsection (c) of said section 26 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis.
Said subsection (c) of said section 26 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Said clause (v) of said subsection (c) of said section 26 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Subsection (d) of said section 26 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors.
Subsection (b) of section 28 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis.
Subsection (c) of said section 28 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis.
Said subsection (c) of said section 28 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Said clause (v) of said subsection (c) of said section 28 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Subsection (d) of said section 28 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors.
Subsection (b) of section 31 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis.
Subsection (c) of said section 31 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis.
Said subsection (c) of said section 31 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Said clause (v) of said subsection (c) of said section 31 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Subsection (d) of said section 31 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors.
Subsection (b) of section 33 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis.
Subsection (c) of said section 33 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis.
Said subsection (c) of said section 33 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Said clause (v) of said subsection (c) of said section 33 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Subsection (d) of said section 33 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors.
Subsection (b) of section 34 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis.
Subsection (c) of said section 34 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis.
Said subsection (c) of said section 34 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Said clause (v) of said subsection (c) of said section 34 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Subsection (d) of said section 34 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors.
Subsection (b) of section 35 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis.
Subsection (c) of said section 35 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis.
Said subsection (c) of said section 35 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Said clause (v) of said subsection (c) of said section 35 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition.
Subsection (d) of said section 35 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors.
This act shall apply to all contracts entered into, renewed or amended on or after July 1, 2026.
SECTION 1. Subsection (b) of section 26 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “members”, the following words:- ; and the following acute condition (i) anaphylaxis. SECTION 2. Subsection (c) of said section 26 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis. SECTION 3. Said subsection (c) of said section 26 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 4. Said clause (v) of said subsection (c) of said section 26 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 5. Subsection (d) of said section 26 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors. SECTION 6. Subsection (b) of section 28 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis. SECTION 7. Subsection (c) of said section 28 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis. SECTION 8. Said subsection (c) of said section 28 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 9. Said clause (v) of said subsection (c) of said section 28 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 10. Subsection (d) of said section 28 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors. SECTION 11. Subsection (b) of section 31 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis. SECTION 12. Subsection (c) of said section 31 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis. SECTION 13. Said subsection (c) of said section 31 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 14. Said clause (v) of said subsection (c) of said section 31 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 15. Subsection (d) of said section 31 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors. SECTION 16. Subsection (b) of section 33 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis. SECTION 17. Subsection (c) of said section 33 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis. SECTION 18. Said subsection (c) of said section 33 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 19. Said clause (v) of said subsection (c) of said section 33 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 20. Subsection (d) of said section 33 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors. SECTION 21. Subsection (b) of section 34 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis. SECTION 22. Subsection (c) of said section 34 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis. SECTION 23. Said subsection (c) of said section 34 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 24. Said clause (v) of said subsection (c) of said section 34 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 25. Subsection (d) of said section 34 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors. SECTION 26. Subsection (b) of section 35 of chapter 342 of the Acts of 2024, is hereby amended by inserting after the word “enrollees”, the following words:- ; and the following acute condition (i) anaphylaxis. SECTION 27. Subsection (c) of said section 35 of said chapter 342, as so appearing, is hereby amended by inserting after the word “diabetes”, the following words:- and epinephrine delivered via an autoinjector as the drug used to treat anaphylaxis. SECTION 28. Said subsection (c) of said section 35 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 29. Said clause (v) of said subsection (c) of said section 35 of said chapter 342, as so appearing, is hereby further amended by inserting after the word “condition”, the following words:- or acute condition. SECTION 30. Subsection (d) of said section 35 of said chapter 342, as so appearing, is hereby amended by adding the following sentence:- Coverage for 1 brand name of epinephrine delivered via an autoinjector or 1 generic brand of epinephrine delivered via an autoinjector shall not be subject to any deductible or co-insurance and any co-payment shall not exceed $60 for a two-pack of epinephrine autoinjectors. SECTION 31. This act shall apply to all contracts entered into, renewed or amended on or after July 1, 2026.